[go: up one dir, main page]

HU903961D0 - Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds - Google Patents

Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds

Info

Publication number
HU903961D0
HU903961D0 HU903961A HU396190A HU903961D0 HU 903961 D0 HU903961 D0 HU 903961D0 HU 903961 A HU903961 A HU 903961A HU 396190 A HU396190 A HU 396190A HU 903961 D0 HU903961 D0 HU 903961D0
Authority
HU
Hungary
Prior art keywords
compounds
oestrenes
beta
aryl
producing
Prior art date
Application number
HU903961A
Other languages
English (en)
Other versions
HUT54705A (en
HU209949B (en
Inventor
Arwed Cleve
Cornelius Scheidges
Guenter Neef
Eshkhard Ottow
Walter Elger
Sybille Beier
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of HU903961D0 publication Critical patent/HU903961D0/hu
Publication of HUT54705A publication Critical patent/HUT54705A/hu
Publication of HU209949B publication Critical patent/HU209949B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0092—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Led Device Packages (AREA)
  • Magnetic Heads (AREA)
  • Pressure Sensors (AREA)
HU903961A 1989-06-23 1990-06-22 Process for the production of 11beta-4-estrene-derivatives and pharmaceutical compositions containing them HU209949B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3921059A DE3921059A1 (de) 1989-06-23 1989-06-23 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel

Publications (3)

Publication Number Publication Date
HU903961D0 true HU903961D0 (en) 1990-11-28
HUT54705A HUT54705A (en) 1991-03-28
HU209949B HU209949B (en) 1994-12-28

Family

ID=6383695

Family Applications (1)

Application Number Title Priority Date Filing Date
HU903961A HU209949B (en) 1989-06-23 1990-06-22 Process for the production of 11beta-4-estrene-derivatives and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (2) US5843933A (hu)
EP (1) EP0404283B1 (hu)
JP (1) JP2911553B2 (hu)
CN (2) CN1048499C (hu)
AT (1) ATE137762T1 (hu)
AU (1) AU640664B2 (hu)
CA (1) CA2019404C (hu)
DD (1) DD295639A5 (hu)
DE (2) DE3921059A1 (hu)
DK (1) DK0404283T3 (hu)
ES (1) ES2088959T3 (hu)
FI (1) FI111844B (hu)
GR (1) GR3020098T3 (hu)
HU (1) HU209949B (hu)
IE (1) IE74191B1 (hu)
IL (1) IL94819A (hu)
NO (1) NO178768C (hu)
PT (1) PT94462A (hu)
ZA (1) ZA904893B (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
IE911870A1 (en) * 1990-06-07 1991-12-18 Mogen Int New antifungal preparations, process for making such¹preparations and process for obtaining plants with decreased¹susceptibility to fungi
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
CA2100514C (en) * 1992-07-29 2005-03-29 Johannes A. M. Hamersma 17-spiromethylene steroids
US5681817A (en) 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
DE4434488A1 (de) * 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
ZA9510926B (en) 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US6090798A (en) * 1997-12-19 2000-07-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with glucocorticoid antagonists
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
KR100348888B1 (en) * 2001-12-11 2002-08-14 Chang Eun Jung Method for relieving violence and spare diet of estrous deer and method for promoting growth of antlers thereof
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20100160275A1 (en) * 2006-09-26 2010-06-24 Lee Eva Y H P Methods and compositions for cancer prevention and treatment
ES2643318T3 (es) 2006-10-24 2017-11-22 Repros Therapeutics Inc. Composiciones y métodos para suprimir la proliferación endometrial
TWI539953B (zh) 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
HUP0900487A2 (hu) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxi-11ß-[4-(dimetil-amino)-fenil]-21-metoxi-19-norpregna-4,9-dién-3,20-dion új kristályos polimorf módosulata és eljárás elõállítására
EP2550288A1 (en) 2010-03-22 2013-01-30 Repros Therapeutics Inc. Compositions and methods for non-toxic delivery of antiprogestins
US11110103B2 (en) 2015-12-23 2021-09-07 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CA3009522A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
CN108713023B (zh) * 2015-12-23 2021-10-26 欧瑞克制药公司 糖皮质激素受体抑制剂
EP3523315B1 (en) 2016-10-07 2021-03-24 Oric Pharmaceuticals, Inc. Inhibitor of glucocorticoid receptor

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2528434B1 (fr) * 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
US4978657A (en) * 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
WO1986001105A1 (en) * 1984-08-02 1986-02-27 Fernand Labrie Pharmaceutical composition for combination therapy of hormone dependent cancers
DE3506785A1 (de) * 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2596395B1 (fr) * 1986-03-26 1989-05-26 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) * 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
US4774236A (en) * 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US4861763A (en) * 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
DE3702383A1 (de) * 1987-01-23 1988-08-04 Schering Ag 11ss-alkinylestrene und -estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2610933B1 (fr) * 1987-02-18 1989-06-09 Roussel Uclaf Nouveaux 19-nor steroides substitues en position 7, leur preparation, leur application comme medicaments, les compositions pharmaceutiques les renfermant
DE3708942A1 (de) * 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2620707B1 (fr) * 1987-09-18 1989-12-08 Roussel Uclaf Nouveaux steroides comportant un cycle spirannique a 3, 4 ou 6 chainons en position 17, leur procede et des intermediaires de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel

Also Published As

Publication number Publication date
CA2019404C (en) 2003-09-16
NO178768B (no) 1996-02-19
ZA904893B (en) 1991-04-24
AU5778090A (en) 1991-01-03
US5843933A (en) 1998-12-01
US5728689A (en) 1998-03-17
EP0404283A3 (de) 1991-07-31
PT94462A (pt) 1991-02-08
IE902280A1 (en) 1991-01-16
ES2088959T3 (es) 1996-10-01
HUT54705A (en) 1991-03-28
IL94819A0 (en) 1991-04-15
CN1133296A (zh) 1996-10-16
CN1061052C (zh) 2001-01-24
NO902800D0 (no) 1990-06-22
IE902280L (en) 1990-12-23
GR3020098T3 (en) 1996-08-31
NO178768C (no) 1996-05-29
IE74191B1 (en) 1997-07-16
CA2019404A1 (en) 1990-12-23
CN1048499C (zh) 2000-01-19
HU209949B (en) 1994-12-28
JP2911553B2 (ja) 1999-06-23
JPH03128323A (ja) 1991-05-31
DD295639A5 (de) 1991-11-07
NO902800L (no) 1990-12-27
AU640664B2 (en) 1993-09-02
DE3921059A1 (de) 1991-01-10
DE59010312D1 (de) 1996-06-13
FI903153A0 (fi) 1990-06-21
FI111844B (fi) 2003-09-30
DK0404283T3 (da) 1996-09-09
EP0404283A2 (de) 1990-12-27
CN1048219A (zh) 1991-01-02
IL94819A (en) 1995-03-30
ATE137762T1 (de) 1996-05-15
EP0404283B1 (de) 1996-05-08

Similar Documents

Publication Publication Date Title
HU903961D0 (en) Process for producing 11-beta-aryl-4-oestrenes and pharmaceutical preparatives containing these compounds
ZW189A1 (en) Chemical compounds
GR3023936T3 (en) Heterocyclic alkylamides, process for their preparation and pharmaceutical compositions containing them
CS919585A3 (en) Novel pyrrolobenzimidazoles, process for their preparation and medicaments comprising thereof
EP0288758A3 (en) Dihydropyridinamides, process for their preparation and their use in medicines
HU903811D0 (en) Process for producing dibenzo (1,5)dioxocine-5-one derivatives and pharmaceutical preparatives containing such compounds
HUT49876A (en) Process for producing 6-oxopyridazine derivatives and pharmaceutical compositions comprising same
HUT59827A (en) Process for producing pharmaceutical compositions containing pafantagonistic thieno-triazolo-diazepines for treating heart diseases produced by diminished beta-receptor-stimulant
HUT55033A (en) Process for producing aminooligohydroxy derivatives and pharmaceutical compositions comprising same
HUT54682A (en) Process for producing 13-bromine- and 13,14-dibromine-ergoline derivatives and pharmaceutical preparatives containing these compounds
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
EP0301401A3 (en) Leukotriene antagonists, process for their preparation, their use in the treatment of illnesses, as well as precursors
IL87198A0 (en) Leukotriene antagonists,a process for the preparation thereof and pharmaceutical compositions containing them
HU905030D0 (en) Process for producing new 1,3-oxazines and pharmaceutical preparatives containing these compounds

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee